TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsProdia makes IDX debut, eyes leadership in clinical laboratory market
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
All smiles: Clinical laboratory services provider Prodia Widyahusada finance director Lianda Kuswandi (left), marketing director Indriyanti Rafi Sukmawati (second left), president director Dewi Muliaty (second right), and Indopremier Securities president director Moleonoto answer journalists' questions in a press conference at the Indonesia Stock Exchange (IDX) on Dec. 7. (JP/Anton Hermansyah)
C
linical laboratory services provider Prodia Widyahusada started on Wednesday its first trading day as a publicly listed company on the Indonesia Stock Exchange (IDX), after cashing in Rp 1.22 trillion (US$91.4 million) from the sales of 20 percent of shares in its initial public offering (IPO).
Prodia finance director Lianda Kuswandi said the company would use 67 percent of the new funds to finance corporate expansion, including the opening of 33 new branches in the next four years, 19 percent to buy new equipment and the remaining 14 percent for working capital.
"The company is striving for healthy business growth under good [corporate] governance," she said at a press conference in the IDX building in Jakarta on Wednesday.
President director Dewi Muliaty, meanwhile, claimed that the company was currently the market leader in the industry, with 35 percent of the market share. By the first half of this year, the company’s revenue had increased 9.7 percent year-on-year (yoy) to Rp 648.6 billion and net profit had surged 22 percent yoy to Rp 32.1 billion, she said.
"Our market share is far ahead the second biggest [player] in the industry. We aim to keep this market share in the future," Dewi said.
The company currently runs 251 outlets in 104 Indonesian cities, with support 3,600 employees and 230 partner doctors. (hwa)
